Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied. By either intravenous or oral administration, the drug was successful in reducing peripheral leukocyte and blast counts in all cases and in reducing splenomegaly in 13 of 17 patients. The median duration of disease control was 75 days in myeloproliferative acceleration and 27 days in frank blastic transformation. Mild nausea and vomiting were experienced by most patients, but reversible bone marrow suppression occured in only three patients. The drug proved useful in 19 patients who demonstrated myeloproliferative acceleration, especially in controlling excessive leukocytosis and/or thrombocytosis. Rapid reduction of an elevated blast cell count was achieved in nine patients who presented in blastic crisis, in an attempt to eliminate the associated risk of cerebral vascular leukostasis. Five patients who required treatment for their disease following splenectomy in the chronic phase were also well controlled. Hydroxyurea appears to have a definite role in the management of these hematologic complications of CGL.
D002066:Busulfan / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D007958:Leukocyte Count; D007964:Leukocytosis / Q000188:drug therapy / Q000209:etiology; D008927:Mitobronitol / Q000627:therapeutic use; D013156:Splenectomy; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D013921:Thrombocytopenia / Q000601:surgery; D013922:Thrombocytosis / Q000209:etiology
D008927:Mitobronitol; D002066:Busulfan; D006918:Hydroxyurea